Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Core Viewpoint - Tandem Diabetes Care, Inc. is under investigation for potential violations of federal securities laws following a malfunction in its insulin pumps that could endanger patients and lead to significant financial losses for investors [1][2]. Company Summary - On August 7, 2025, Tandem disclosed a malfunction in some of its insulin pumps that could lead to a discontinuation of insulin delivery, potentially resulting in hyperglycemia and requiring hospitalization [2]. - The company notified affected customers between July 22 and 24, 2025, about the issue [2]. - Following this announcement, Tandem's stock price dropped by $2.87, or 19.9%, closing at $11.52 per share on the same day, indicating a significant impact on investor value [3]. Legal and Investigation Context - Glancy Prongay & Murray LLP is leading the investigation on behalf of Tandem investors to explore possible claims for recovering losses incurred due to the stock price decline [1][4]. - The law firm has a strong track record in securities litigation, having recovered billions for investors and consistently ranked among the top firms in securities class action settlements [6][7].